Type 1 Diabetes Breakthrough
FDA Approves Sanofi's Tzield as First Disease-Modifying Therapy for Type 1 Diabetes
Anonymous
The FDA has approved Sanofi's Tzield (teplizumab-mzwv) as the first disease-modifying therapy for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes. The June 12, 2026 decision marks a historic shift — for the first time, a drug can slow the immune attack destroying the pancreas in newly diagnosed patients, not just prevent the disease from starting. GlobeNewswire reported the approval was granted under accelerated review.
About 64,000 to 65,000 people are diagnosed with type 1 diabetes in the US every year, according to Sanofi. Until now, every treatment option focused on managing insulin levels — not stopping the disease itself.
What Tzield Does and How It Works
Type 1 diabetes is an autoimmune disease. The body's immune system attacks beta cells — the cells in the pancreas that make insulin. Once those cells are gone, they don't come back. Tzield is a CD3-directed monoclonal antibody, meaning it targets a key part of the immune system and reprograms it to stop that attack. The goal is to preserve as many beta cells as possible while they still exist.
Doctors measure beta cell function using C-peptide levels — a protein released when insulin is made. In the PROTECT Phase 3 trial, Tzield produced a 0.13 pmol/mL improvement in C-peptide levels compared to placebo (p<0.001), according to data published in The New England Journal of Medicine. That means patients on Tzield kept more of their natural insulin production than those who received a dummy treatment.
A 14-Day Infusion With a $200,000 Price Tag
Tzield is not a pill or a weekly shot. Patients receive a 14-day course of continuous IV infusions — meaning they must visit a specialty infusion center every day for two weeks. That logistical burden is a real barrier, especially for patients in rural or low-income areas, according to diaTribe.
The cost is steep. Each vial runs roughly $14,411, and a full treatment course costs about $201,753, according to diaTribe. Sanofi has launched the TZIELD COMPASS program to help patients with access and co-pays. Still, analysts at Jefferies have flagged the price and infusion schedule as potential barriers to widespread use, per FirstWord Pharma.
Breakthrough Approval Comes With Unanswered Questions
The FDA approval is called
What Comes Next for T1D Treatment
Tzield's approval adds pressure to expand diabetes screening. To benefit from the drug, patients must be caught early — either in Stage 2 (before symptoms appear) or right at the start of Stage 3. That means testing for autoantibodies, proteins in the blood that signal the immune attack has begun, long before a child feels sick.
Competition is coming. diaTribe reported that SAB Biotherapeutics is recruiting for SAB-142, a rival therapy that may require just a 2-day infusion instead of 14 days and could allow repeat dosing. Sanofi also won a separate FDA approval in April 2026 to use Tzield in children aged 1 to 7 with Stage 2 T1D, according to Drugs.com. Christopher Corsico, Sanofi's Global Head of Development, said the drug aims to impact T1D's
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
6
Articles
4
Reach
6
A
AnonymousAuthor
